Glaukos Medical Corp. is slowly proving its stent used in the treatment of glaucoma can be used as a standalone therapy, dispelling the idea the device must be used in conjunction with cataract procedures. The San Clemente, Calif.-based company, which competes in the Micro-Invasive Glaucoma Surgery (MIGS) space, revealed hard data in the form of a 53 open-angle glaucoma patient study.